Search

Your search keyword '"Jakobsen, Lasse H."' showing total 159 results
Start Over Author "Jakobsen, Lasse H."
159 results on '"Jakobsen, Lasse H."'

1. Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

Author

Lee, Rebecca J., Wysocki, Oskar, Zhou, Cong, Shotton, Rohan, Tivey, Ann, Lever, Louise, Woodcock, Joshua, Albiges, Laurence, Angelakas, Angelos, Arnold, Dirk, Aung, Theingi, Banfill, Kathryn, Baxter, Mark, Barlesi, Fabrice, Bayle, Arnaud, Besse, Benjamin, Bhogal, Talvinder, Boyce, Hayley, Britton, Fiona, Calles, Antonio, Castelo-Branco, Luis, Copson, Ellen, Croitoru, Adina E., Dani, Sourbha S., Dickens, Elena, Eastlake, Leonie, Fitzpatrick, Paul, Foulon, Stephanie, Frederiksen, Henrik, Frost, Hannah, Ganatra, Sarju, Gennatas, Spyridon, Glenthøj, Andreas, Gomes, Fabio, Graham, Donna M., Hague, Christina, Harrington, Kevin, Harrison, Michelle, Horsley, Laura, Hoskins, Richard, Huddar, Prerana, Hudson, Zoe, Jakobsen, Lasse H., Joharatnam-Hogan, Nalinie, Khan, Sam, Khan, Umair T., Khan, Khurum, Massard, Christophe, Maynard, Alec, McKenzie, Hayley, Michielin, Olivier, Mosenthal, Anne C., Obispo, Berta, Patel, Rushin, Pentheroudakis, George, Peters, Solange, Rieger-Christ, Kimberly, Robinson, Timothy, Rogado, Jacobo, Romano, Emanuela, Rowe, Michael, Sekacheva, Marina, Sheehan, Roseleen, Stevenson, Julie, Stockdale, Alexander, Thomas, Anne, Turtle, Lance, Viñal, David, Weaver, Jamie, Williams, Sophie, Wilson, Caroline, Palmieri, Carlo, Landers, Donal, Cooksley, Timothy, Dive, Caroline, Freitas, André, and Armstrong, Anne C.

Published
2022
Full Text
View/download PDF

2. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study

Author

Pedersen, Mette Abildgaard, primary, Gormsen, Lars C., additional, Jakobsen, Lasse H., additional, Eyre, Toby A., additional, Severinsen, Marianne T., additional, Baech, Joachim, additional, Dann, Eldad J., additional, Knapp, Andrea, additional, Sahin, Denis, additional, Vestergaard, Peter, additional, El‐Galaly, Tarec C., additional, and Jensen, Paw, additional

Published
2023
Full Text
View/download PDF

3. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.

Author

Pedersen, Mette Abildgaard, Gormsen, Lars C., Jakobsen, Lasse H., Eyre, Toby A., Severinsen, Marianne T., Baech, Joachim, Dann, Eldad J., Knapp, Andrea, Sahin, Denis, Vestergaard, Peter, El‐Galaly, Tarec C., and Jensen, Paw

Subjects
BONE density, VERTEBRAL fractures, GALLIUM, REMISSION induction, FOLLICULAR lymphoma
Abstract

Summary: Standard CHOP treatment includes a high cumulative dose of prednisone, and studies have shown increased fracture risk following CHOP. It is unclear whether reductions in bone mineral density (BMD) are caused by glucocorticoids or by the combination with chemotherapy. Our objective was to determine the effect of obinutuzumab (G)/rituximab (R)‐bendamustine versus G/R‐CHOP on BMD in follicular lymphoma patients. Patients in this GALLIUM post hoc study were ≥60 years old and in complete remission at induction treatment completion (ITC), following treatment with G or R in combination with bendamustine or CHOP. To assess BMD, Hounsfield units (HU) were measured in lumbar vertebra L1 on annual computed tomography. Furthermore, vertebral compression fractures were recorded. Of 173 patients included, 59 (34%) received CHOP and 114 (66%) received bendamustine. At baseline, there was no difference in HU between groups. The mean HU decrease from baseline to ITC was 27.8 after CHOP and 17.3 after bendamustine, corresponding to a difference of 10.4 (95% CI: 3.2–17.6). Vertebral fractures were recorded in 5/59 patients receiving CHOP and in 2/114 receiving bendamustine. CHOP was associated with a significant greater decrease in BMD and more frequent fractures. These results suggest that prophylaxis against BMD loss should be considered. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Reproduction patterns among non‐Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population‐based matched cohort study

Author

Entrop, Joshua P., primary, Weibull, Caroline E., additional, Smedby, Karin E., additional, Jakobsen, Lasse H., additional, Øvlisen, Andreas K., additional, Glimelius, Ingrid, additional, Marklund, Anna, additional, Larsen, Thomas S., additional, Holte, Harald, additional, Fosså, Alexander, additional, Smeland, Knut B., additional, El‐Galaly, Tarec C., additional, and Eloranta, Sandra, additional

Published
2023
Full Text
View/download PDF

5. Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway:A population-based matched cohort study

Author

Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Øvlisen, Andreas K., Glimelius, Ingrid, Marklund, Anna, Larsen, Thomas S., Holte, Harald, Fosså, Alexander, Smeland, Knut B., El-Galaly, Tarec C., and Eloranta, Sandra

Subjects
fertility, non-Hodgkin lymphoma, late effects of therapy
Abstract

Previous studies concerning reproductive patterns among non-Hodgkin lymphoma (NHL) survivors are scarce and those available have reported conflicting results. Treatment regimens vary considerably between aggressive and indolent NHL and studies of reproductive patterns by subtypes are warranted. In this matched cohort study, we identified all NHL patients aged 18–40 years and diagnosed between 2000 and 2018 from the Swedish and Danish lymphoma registers, and the clinical database at Oslo University Hospital (n = 2090). Population comparators were matched on sex, birth year and country (n = 19 427). Hazard ratios (HRs) were estimated using Cox regression. Males and females diagnosed with aggressive lymphoma subtypes had lower childbirth rates (HRfemale: 0.43, 95% CI: 0.31–0.59, HRmale: 0.61, 95% CI: 0.47–0.78) than comparators during the first 3 years after diagnosis. For indolent lymphomas, childbirth rates were not significantly different from comparators (HRfemale: 0.71, 95% CI: 0.48–1.04, HRmale: 0.94, 95% CI: 0.70–1.27) during the same period. Childbirth rates reached those of comparators for all subtypes after 3 years but the cumulative incidence of childbirths was decreased throughout the 10-year follow-up for aggressive NHL. Children of NHL patients were more likely to be born following assisted reproductive technology than those of comparators, except for male indolent lymphoma patients. In conclusion, fertility counselling is particularly important for patients with aggressive NHL.

Published
2023
Full Text
View/download PDF

7. Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway : A population-based matched cohort study

Author

Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Ovlisen, Andreas K., Glimelius, Ingrid, Marklund, Anna, Larsen, Thomas S., Holte, Harald, Fossa, Alexander, Smeland, Knut B., El-Galaly, Tarec C., Eloranta, Sandra, Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Ovlisen, Andreas K., Glimelius, Ingrid, Marklund, Anna, Larsen, Thomas S., Holte, Harald, Fossa, Alexander, Smeland, Knut B., El-Galaly, Tarec C., and Eloranta, Sandra

Abstract

Previous studies concerning reproductive patterns among non-Hodgkin lymphoma (NHL) survivors are scarce and those available have reported conflicting results. Treatment regimens vary considerably between aggressive and indolent NHL and studies of reproductive patterns by subtypes are warranted. In this matched cohort study, we identified all NHL patients aged 18-40 years and diagnosed between 2000 and 2018 from the Swedish and Danish lymphoma registers, and the clinical database at Oslo University Hospital (n = 2090). Population comparators were matched on sex, birth year and country (n = 19 427). Hazard ratios (HRs) were estimated using Cox regression. Males and females diagnosed with aggressive lymphoma subtypes had lower childbirth rates (HRfemale: 0.43, 95% CI: 0.31-0.59, HRmale: 0.61, 95% CI: 0.47-0.78) than comparators during the first 3 years after diagnosis. For indolent lymphomas, childbirth rates were not significantly different from comparators (HRfemale: 0.71, 95% CI: 0.48-1.04, HRmale: 0.94, 95% CI: 0.70-1.27) during the same period. Childbirth rates reached those of comparators for all subtypes after 3 years but the cumulative incidence of childbirths was decreased throughout the 10-year follow-up for aggressive NHL. Children of NHL patients were more likely to be born following assisted reproductive technology than those of comparators, except for male indolent lymphoma patients. In conclusion, fertility counselling is particularly important for patients with aggressive NHL.

Published
2023
Full Text
View/download PDF

8. Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study

Author

Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Øvlisen, Andreas K., Molin, Daniel, Glimelius, Ingrid, Marklund, Anna, Holte, Harald, Fosså, Alexander, Smeland, Knut B., El-Galaly, Tarec C., Eloranta, Sandra, Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Øvlisen, Andreas K., Molin, Daniel, Glimelius, Ingrid, Marklund, Anna, Holte, Harald, Fosså, Alexander, Smeland, Knut B., El-Galaly, Tarec C., and Eloranta, Sandra

Abstract

Childbirth rates in classical Hodgkin lymphoma (cHL) survivors have historically been reduced compared to the general population. Understanding if contemporary treatment protocols are associated with reduced fertility is crucial as treatment guidelines shift toward more liberal use of intensive chemotherapy. We identified 2834 individuals aged 18-40 years with cHL in Swedish and Danish lymphoma registers, and in the clinical database at Oslo University Hospital diagnosed 1995-2018, who were linked to national medical birth registers. Cox regression adjusted for stage, performance status, year, and age at diagnosis was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) contrasting time to first childbirth by treatment groups (ABVD, 2-4 BEACOPP, 6-8 BEACOPP) up to 10 years after diagnosis. Overall, 74.8% of patients were treated with ABVD, 3.1% with 2-4 BEACOPP and 11.2% with 6-8 BEACOPP. Adjusted HRs comparing childbirth rates in individuals treated with 6-8 BEACOPP, and 2-4 BEACOPP to ABVD were 0.53 (CI: 0.36-0.77) and 0.33 (CI: 0.12-0.91) for males, and 0.91 (CI: 0.61-1.34) and 0.38 (CI: 0.12-1.21) for females. Cumulative incidence of childbirths after 10 years was 19.8% (CI: 14.5%-27.0%) for males and 34.3% (CI: 25.8%-45.6%) for females treated with 6-8 BEACOPP. Proportions of children born after assisted reproductive technique (ART) treatments were 77.4% (CI: 60.2-88.6%) for males following 6-8 BEACOPP, and <11% for females. Among ABVD treated patients the corresponding proportions were 12.2% (CI: 8.5%-17.3%) and 10.6% (CI: 7.4%-14.9%). BEACOPP treatment is associated with decreased childbirth rates compared to ABVD in male, but not female, cHL patients, despite widespread access to ART in the Nordics.

Published
2023
Full Text
View/download PDF

9. Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020:A Danish population-based cohort study

Author

Gjærde, Lars K., Jakobsen, Lasse H, Juhl-Christensen, Caroline, Olesen, Gitte, Petruskevicius, Irma, Severinsen, Marianne T, Marcher, Claus W, Theilgaard-Mönch, Kim, Andersen, Niels S, Friis, Lone S, Kornblit, Brian, Petersen, Søren L, Schjødt, Ida, Sengeløv, Henrik, Gjærde, Lars K., Jakobsen, Lasse H, Juhl-Christensen, Caroline, Olesen, Gitte, Petruskevicius, Irma, Severinsen, Marianne T, Marcher, Claus W, Theilgaard-Mönch, Kim, Andersen, Niels S, Friis, Lone S, Kornblit, Brian, Petersen, Søren L, Schjødt, Ida, and Sengeløv, Henrik

Published
2023

10. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

Author

Lewis, Katharine L., Jakobsen, Lasse H., Villa, Diego, Smedby, Karin E., Savage, Kerry J., Eyre, Toby A., Cwynarski, Kate, Bishton, Mark J., Fox, Christopher P., Hawkes, Eliza A., Maurer, Matthew J., El-Galaly, Tarec C., Cheah, Chan Y., Bobillo, Sabela, Caporn, Paris L., Van Zyl, Joan, Klanova, Magdalena, Trněny, Marek, Puckrin, Robert, and Stewart, Douglas A.

Published
2023
Full Text
View/download PDF

11. Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway—A population‐based matched cohort study

Author

Entrop, Joshua P., primary, Weibull, Caroline E., additional, Smedby, Karin E., additional, Jakobsen, Lasse H., additional, Øvlisen, Andreas K., additional, Molin, Daniel, additional, Glimelius, Ingrid, additional, Marklund, Anna, additional, Holte, Harald, additional, Fosså, Alexander, additional, Smeland, Knut B., additional, El‐Galaly, Tarec C., additional, and Eloranta, Sandra, additional

Published
2023
Full Text
View/download PDF

12. Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population‐based cohort study

Author

Gjærde, Lars K., primary, Jakobsen, Lasse H., additional, Juhl‐Christensen, Caroline, additional, Olesen, Gitte, additional, Petruskevicius, Irma, additional, Severinsen, Marianne T., additional, Marcher, Claus W., additional, Theilgaard‐Mönch, Kim, additional, Andersen, Niels S., additional, Friis, Lone S., additional, Kornblit, Brian, additional, Petersen, Søren L., additional, Schjødt, Ida, additional, and Sengeløv, Henrik, additional

Published
2022
Full Text
View/download PDF

13. Multiplex proteomics as risk predictor of infection in patients treated with hemodialysis-A prospective multicenter study

Author

Glerup, Rie, Svensson, My, Jakobsen, Lasse H., Fellström, Bengt, Jensen, Jens D., Christensen, Jeppe H., Glerup, Rie, Svensson, My, Jakobsen, Lasse H., Fellström, Bengt, Jensen, Jens D., and Christensen, Jeppe H.

Abstract

Introduction Severe infection is a major problem in hemodialysis patients. Multiplex proteomics might reveal novel insights into disease mechanisms increasing the risk of infection and might also be used as a risk prediction tool. The aims of this study were (1) to evaluate associations between 92 proteins assessed by a proximity extension assay and the development of severe infection in patients on hemodialysis and (2) to develop a risk prediction model for severe infection using prespecified clinical variables and proteomics. Methods Prospective, observational multicenter cohort study with 5-year follow-up. Patients receiving in-center hemodialysis in five facilities in Denmark were included. The primary composite endpoint was death caused by infection, bacteremia, and infections requiring hospitalization of at least 2 days or prolonging a hospital stay. Findings Of 331 patients included 210 patients reached the primary endpoint during follow-up. In adjusted Cox regression analyses, 14 plasma proteins were associated with severe infection. Correcting for multiple testing revealed only cathepsin-L1 and interleukin-6 significantly associated with the primary outcome. Cathepsin-L1-hazard ratio: 1.64 (95% confidence interval [CI] 1.24-2.17) and interleukin-6-hazard ratio: 1.16 (95% CI 1.05-1.29). Apparent C-statistics of the risk prediction model using clinical variables was 0.605, addition of cathepsin-L1 and interleukin-6 to the model improved discrimination slightly: C = 0.625. Discussion Proteomic profiling identified cathepsin-L1 and interleukin-6 as markers for infectious risk in hemodialysis patients. Further studies are needed to replicate the results and to examine possible causality. The developed risk prediction models need considerable improvement before implementation in clinical practice is meaningful.

Published
2022
Full Text
View/download PDF

14. An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

Author

Wysocki, Oskar, Zhou, Cong, Rogado, Jacobo, Huddar, Prerana, Shotton, Rohan, Tivey, Ann, Albiges, Laurence, Angelakas, Angelos, Arnold, Dirk, Aung, Theingi, Banfill, Kathryn, Baxter, Mark, Barlesi, Fabrice, Bayle, Arnaud, Besse, Benjamin, Bhogal, Talvinder, Boyce, Hayley, Britton, Fiona, Calles, Antonio, Castelo-Branco, Luis, Copson, Ellen, Croitoru, Adina, Dani, Sourbha S., Dickens, Elena, Eastlake, Leonie, Fitzpatrick, Paul, Foulon, Stephanie, Frederiksen, Henrik, Ganatra, Sarju, Gennatas, Spyridon, Glenthøj, Andreas, Gomes, Fabio, Graham, Donna M., Hague, Christina, Harrington, Kevin, Harrison, Michelle, Horsley, Laura, Hoskins, Richard, Hudson, Zoe, Jakobsen, Lasse H., Joharatnam-Hogan, Nalinie, Khan, Sam, Khan, Umair T., Khan, Khurum, Lewis, Alexandra, Massard, Christophe, Maynard, Alec, McKenzie, Hayley, Michielin, Olivier, Mosenthal, Anne C., Wysocki, Oskar, Zhou, Cong, Rogado, Jacobo, Huddar, Prerana, Shotton, Rohan, Tivey, Ann, Albiges, Laurence, Angelakas, Angelos, Arnold, Dirk, Aung, Theingi, Banfill, Kathryn, Baxter, Mark, Barlesi, Fabrice, Bayle, Arnaud, Besse, Benjamin, Bhogal, Talvinder, Boyce, Hayley, Britton, Fiona, Calles, Antonio, Castelo-Branco, Luis, Copson, Ellen, Croitoru, Adina, Dani, Sourbha S., Dickens, Elena, Eastlake, Leonie, Fitzpatrick, Paul, Foulon, Stephanie, Frederiksen, Henrik, Ganatra, Sarju, Gennatas, Spyridon, Glenthøj, Andreas, Gomes, Fabio, Graham, Donna M., Hague, Christina, Harrington, Kevin, Harrison, Michelle, Horsley, Laura, Hoskins, Richard, Hudson, Zoe, Jakobsen, Lasse H., Joharatnam-Hogan, Nalinie, Khan, Sam, Khan, Umair T., Khan, Khurum, Lewis, Alexandra, Massard, Christophe, Maynard, Alec, McKenzie, Hayley, Michielin, Olivier, and Mosenthal, Anne C.

Abstract

Patients with cancer have been shown to have increased risk of COVID-19 severity. We previously built and validated the COVID-19 Risk in Oncology Evaluation Tool (CORONET) to predict the likely severity of COVID-19 in patients with active cancer who present to hospital. We assessed the differences in presentation and outcomes of patients with cancer and COVID-19, depending on the wave of the pandemic. We examined differences in features at presentation and outcomes in patients worldwide, depending on the waves of the pandemic: wave 1 D614G (n = 1430), wave 2 Alpha (n = 475), and wave 4 Omicron variant (n = 63, UK and Spain only). The performance of CORONET was evaluated on 258, 48, and 54 patients for each wave, respectively. We found that mortality rates were reduced in subsequent waves. The majority of patients were vaccinated in wave 4, and 94% were treated with steroids if they required oxygen. The stages of cancer and the median ages of patients significantly differed, but features associated with worse COVID-19 outcomes remained predictive and did not differ between waves. The CORONET tool performed well in all waves, with scores in an area under the curve (AUC) of >0.72. We concluded that patients with cancer who present to hospital with COVID-19 have similar features of severity, which remain discriminatory despite differences in variants and vaccination status. Survival improved following the first wave of the pandemic, which may be associated with vaccination and the increased steroid use in those patients requiring oxygen. The CORONET model demonstrated good performance, independent of the SARS-CoV-2 variants.

Published
2022

15. Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders

Author

Glenthøj, Andreas, Jakobsen, Lasse H., Bjørn, Mads Emil, Poulsen, Christian B., Sengeløv, Henrik, Severinsen, Marianne T., Qvist, Kristian, Overgaard, Ulrik M., Ahmad, Syed A., Rewes, Annika, Mølle, Ingolf, Strandholdt, Casper N., Kodahl, Annette R., Ryg, Jesper, Brieghel, Christian, Johansen, Isik S., Kannik, Karina, Jensen-Fangel, Søren, Wiese, Lothar, Kirk, Ole, Clausen, Michael R., Helleberg, Marie, Frederiksen, Henrik, Glenthøj, Andreas, Jakobsen, Lasse H., Bjørn, Mads Emil, Poulsen, Christian B., Sengeløv, Henrik, Severinsen, Marianne T., Qvist, Kristian, Overgaard, Ulrik M., Ahmad, Syed A., Rewes, Annika, Mølle, Ingolf, Strandholdt, Casper N., Kodahl, Annette R., Ryg, Jesper, Brieghel, Christian, Johansen, Isik S., Kannik, Karina, Jensen-Fangel, Søren, Wiese, Lothar, Kirk, Ole, Clausen, Michael R., Helleberg, Marie, and Frederiksen, Henrik

Abstract

Background Particularly older patients and patients with comorbidities have been reported to suffer from complications and fatalities due to coronavirus disease 2019 (COVID-19) [Citation1–5]. COVID-19 has given rise to a case-fatality rate (CFR) above 20% in cancer patients compared to 5–6% in non-cancer patients [Citation6–11]. Patients with haematological cancers have demonstrated the highest CFRs, often exceeding 30% [Citation9,Citation12,Citation13]. Emphasising the vulnerability, seroconversion 21 days after COVID-19 vaccination was 94% in healthy controls compared with 18% in patients with haematological cancer [Citation14]. Almost all previous studies have investigated prognosis using mortality rate at 30 days or CFR without specified follow-up period [Citation7,Citation15–17] and prognosis data beyond one month is scarce [Citation12,Citation18,Citation19]. Since patients with haematological cancer may have a delayed or even absent clearance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [Citation20], studies with longer-term follow-up are relevant to monitor mortality and post infection symptoms. Recently it was reported that even SARS-CoV-2 infected patients that were not hospitalised, more frequently initiated bronchodilating agents or received a subsequent hospital diagnosis of dyspnoea than matched SARS-CoV-2 negative comparisons [Citation21]. Similarly, we found that among 66 patients with haematological disease and SARS-CoV-2 infection, 57% reported fatigue, 46% reduced functional abilities, and 33% dyspnoea one month after verified infection [Citation22]. In the present study, we extended inclusion period and follow-up to include additional patients and study mortality and functional capacity 90-days after SARS-CoV-2 infection. Herein we present data regarding clinical presentation and outcome for 108 adult Danish patients with haematological disease and SARS-CoV-2 infection verified before September 1, 2020.

Published
2022

17. Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population‐based cohort study.

Author

Gjærde, Lars K., Jakobsen, Lasse H., Juhl‐Christensen, Caroline, Olesen, Gitte, Petruskevicius, Irma, Severinsen, Marianne T., Marcher, Claus W., Theilgaard‐Mönch, Kim, Andersen, Niels S., Friis, Lone S., Kornblit, Brian, Petersen, Søren L., Schjødt, Ida, and Sengeløv, Henrik

Subjects
*ACUTE myeloid leukemia, *CELL transplantation, *COHORT analysis, *HEMATOPOIETIC stem cell transplantation, *CORD blood
Published
2023
Full Text
View/download PDF

18. Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders

Author

Glenthøj, Andreas, primary, Jakobsen, Lasse H., additional, Bjørn, Mads Emil, additional, Poulsen, Christian B., additional, Sengeløv, Henrik, additional, Severinsen, Marianne T., additional, Qvist, Kristian, additional, Overgaard, Ulrik M., additional, Ahmad, Syed A., additional, Rewes, Annika, additional, Mølle, Ingolf, additional, Strandholdt, Casper N., additional, Kodahl, Annette R., additional, Ryg, Jesper, additional, Brieghel, Christian, additional, Johansen, Isik S., additional, Kannik, Karina, additional, Jensen-Fangel, Søren, additional, Wiese, Lothar, additional, Kirk, Ole, additional, Clausen, Michael R., additional, Helleberg, Marie, additional, and Frederiksen, Henrik, additional

Published
2022
Full Text
View/download PDF

20. The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP

Author

Severinsen, Freja Tang, primary, Haunstrup, Laura Mors, additional, Jensen, Rasmus Kuhr, additional, Maurer, Matthew J., additional, Khurana, Arushi, additional, Jensen, Paw, additional, Jørgensen, Judit M., additional, Larsen, Thomas Stauffer, additional, Clausen, Michael Roost, additional, Poulsen, Christian Bjørn, additional, Brown, Peter de Nully, additional, El-Galaly, Tarec Christoffer, additional, and Jakobsen, Lasse H., additional

Published
2021
Full Text
View/download PDF

21. Risk of Incident Diabetes and Dysregulated Pre-Existing Diabetes Mellitus in Newly Diagnosed Lymphoma Patients Treated with Steroid-Containing Immunochemotherapy: A Danish Population-Based Study

Author

Baech, Joachim, primary, Severinsen, Marianne Tang, additional, Øvlisen, Andreas Kiesbye, additional, Frederiksen, Henrik, additional, Vestergaard, Peter, additional, Torp-Pedersen, Christian, additional, Jørgensen, Judit M., additional, Clausen, Michael Roost, additional, Poulsen, Christian Bjørn, additional, Brown, Peter de Nully, additional, Ortved Gang, Anne, additional, Pedersen, Robert Schou, additional, Ekstroem Smedby, Karin, additional, Eloranta, Sandra, additional, Jakobsen, Lasse H., additional, and El-Galaly, Tarec Christoffer, additional

Published
2021
Full Text
View/download PDF

22. A Randomized Placebo-Controlled Trial of Primary Prophylaxis with Weekly Alendronate Against Glucocorticoid-Induced Osteoporosis in Lymphoma Patients Treated with Steroid-Containing Chemotherapy.

Author

Jensen, Paw, primary, Jakobsen, Lasse H., additional, Bøgsted, Martin, additional, Baech, Joachim, additional, Lykkeboe, Simon, additional, Severinsen, Marianne Tang, additional, Vestergaard, Peter, additional, and El-Galaly, Tarec Christoffer, additional

Published
2021
Full Text
View/download PDF

23. High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients

Author

Lewis, Katharine Louise, primary, Jakobsen, Lasse H., additional, Villa, Diego, additional, Bobillo, Sabela, additional, Ekstroem Smedby, Karin, additional, Savage, Kerry J., additional, Eyre, Toby A., additional, Cwynarski, Kate, additional, Caporn, Paris L, additional, Zyl, Joan Van, additional, Klanova, Magdalena, additional, Trněný, Marek, additional, Puckrin, Robert, additional, Stewart, Douglas A., additional, Bishton, Mark J, additional, Fox, Christopher P., additional, Tun, Aung M, additional, Thanarajasingam, Gita, additional, Djebbari, Faouzi, additional, Joffe, Erel, additional, Eloranta, Sandra, additional, Harrysson, Sara, additional, Sehn, Laurie H., additional, Maliske, Seth M, additional, Poonsombudlert, Kittika, additional, Guo, Xiao, additional, Hapgood, Greg, additional, Manos, Kate, additional, Hawkes, Eliza, additional, Khwaja, Jahanzaib, additional, Minson, Adrian, additional, Dickinson, Michael, additional, Øvlisen, Andreas Kiesbye, additional, Gregory, Gareth P, additional, Gilbertson, Michael, additional, Streit, Isaac T, additional, Scott, Hamish W, additional, Ku, Matthew, additional, de Mel, Sanjay, additional, Yong, Kar Ying, additional, Xin, Liu, additional, Mokoonlall, Mridula, additional, Talaulikar, Dipti, additional, McVilly, Nicholas L, additional, Johnston, Anna, additional, Brunner, Matthew J, additional, Pophali, Priyanka A, additional, Maurer, Matthew J., additional, El-Galaly, Tarec Christoffer, additional, and Cheah, Chan Yoon, additional

Published
2021
Full Text
View/download PDF

24. Mental Health Among Patients with Non-Hodgkin Lymphoma: A Danish Nationwide Study of Psychotropic Drug Use in 7,201 Patients and 36,005 Matched Comparators

Author

Øvlisen, Andreas Kiesbye, primary, Jakobsen, Lasse H., additional, Kragholm, Kristian Hay, additional, Nielsen, René Ernst, additional, Brown, Peter De Nully, additional, Dahl-Soerensen, Rasmus Bo, additional, Frederiksen, Henrik, additional, Mannering, Nikolaj, additional, Josefsson, Pär L., additional, Al-Mashhadi, Ahmed, additional, Jørgensen, Judit M., additional, Dessau-Arp, Andriette, additional, Clausen, Michael Roost, additional, Pedersen, Robert Schou, additional, Torp-Pedersen, Christian, additional, Severinsen, Marianne Tang, additional, and El-Galaly, Tarec Christoffer, additional

Published
2021
Full Text
View/download PDF

25. Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium

Author

Maurer, Matthew J., primary, Prochazka, Vit K, additional, Flowers, Christopher R., additional, Jakobsen, Lasse H., additional, Villa, Diego, additional, Weibull, Caroline, additional, Cahn, Elliot J., additional, Ghesquieres, Herve, additional, Kridel, Robert, additional, Gandhi, Maher, additional, Cheah, Chan Yoon, additional, Hawkes, Eliza, additional, Seymour, John F., additional, Freeman, Ciara L., additional, Clausen, Michael Roost, additional, Wahlin, Björn, additional, Link, Brian K., additional, Ekstroem Smedby, Karin, additional, Sehn, Laurie H., additional, Trněný, Marek, additional, El-Galaly, Tarec Christoffer, additional, and Cerhan, James R., additional

Published
2021
Full Text
View/download PDF

27. Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study

Author

Øvlisen, Andreas K., primary, Jakobsen, Lasse H., additional, Eloranta, Sandra, additional, Kragholm, Kristian H., additional, Hutchings, Martin, additional, Frederiksen, Henrik, additional, Kamper, Peter, additional, Dahl-Sørensen, Rasmus Bo, additional, Stoltenberg, Danny, additional, Weibull, Caroline E., additional, Entrop, Joshua P., additional, Glimelius, Ingrid, additional, Smedby, Karin E., additional, Torp-Pedersen, Christian, additional, Severinsen, Marianne T., additional, and El-Galaly, Tarec C., additional

Published
2021
Full Text
View/download PDF

28. The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Author

Olszewski, Adam J, Jakobsen, Lasse H., Collins, Graham P., Cwynarski, Kate, Bachanova, Veronika, Blum, Kristie A., Boughan, Kirsten M, Bower, Mark, Dalla Pria, Alessia, Danilov, Alexey, David, Kevin A., Diefenbach, Catherine, Ellin, Fredrik, Epperla, Narendranath, Farooq, Umar, Feldman, Tatyana A., Gerrie, Alina S., Jagadeesh, Deepa, Kamdar, Manali, Karmali, Reem, Kassam, Shireen, Kenkre, Vaishalee P., Khan, Nadia, Klein, Andreas, Lossos, Izidore S., Lunning, Matthew A., Martin, Peter, Martinex-Calle, Nicolas, Montoto, Silvia, Naik, Seema, Palmisiano, Neil, Peace, David, Phillips, Elizabeth H, Phillips, Tycel J., Portell, Craig A., Reddy, Nishitha, Santarsieri, Anna, Yazdy, Maryam Sarraf, Smeland, Knut B., Smith, Scott E., Smith, Stephen D., Sundaram, Suchitra, Venugopal, Parameswaran, Zayac, Adam, Zhang, Xiao-Yin, Zhu, Catherine, Cheah, Chan Yoon, El-Galaly, Tarec Christoffer, and Evens, Andrew M.

Published
2020
Full Text
View/download PDF

29. Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors : A Danish Population-Based Study

Author

Ovlisen, Andreas K., Jakobsen, Lasse H., Eloranta, Sandra, Kragholm, Kristian H., Hutchings, Martin, Frederiksen, Henrik, Kamper, Peter, Dahl-Sorensen, Rasmus Bo, Stoltenberg, Danny, Weibull, Caroline E., Entrop, Joshua P., Glimelius, Ingrid, Smedby, Karin E., Torp-Pedersen, Christian, Severinsen, Marianne T., El-Galaly, Tarec C., Ovlisen, Andreas K., Jakobsen, Lasse H., Eloranta, Sandra, Kragholm, Kristian H., Hutchings, Martin, Frederiksen, Henrik, Kamper, Peter, Dahl-Sorensen, Rasmus Bo, Stoltenberg, Danny, Weibull, Caroline E., Entrop, Joshua P., Glimelius, Ingrid, Smedby, Karin E., Torp-Pedersen, Christian, Severinsen, Marianne T., and El-Galaly, Tarec C.

Abstract

PURPOSE The majority of young adults with Hodgkin lymphoma (HL) are cured, but chemotherapy-induced infertility can have profound psychosocial consequences. Providing data on parenthood rates and use of assisted reproductive techniques (ARTs) after contemporary HL treatment is important for patient counseling and survivorship care. MATERIALS AND METHODS All Danish patients with HL diagnosed during 2000-2015 at the ages 18-40 years who achieved remission after first-line therapy were included and matched on age, sex, and parenthood status to five random persons from the general population. Parenthood rates were defined as the rate of first live birth per 1,000 person years, starting 9 months after HL diagnosis. Nationwide birth and patient registers were used to capture parenthood outcomes and ARTs use. RESULTS A total of 793 HL survivors and 3,965 comparators were included (median follow-up 8.7 years). Similar parenthood rates were observed for male and female HL survivors when compared with matched comparators (56.2 v 57.1; P = .871 for males and 63.8 v 61.2; P = .672 for females). For male HL survivors, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) therapy was associated with lower parenthood rates as compared to the matched comparators (28.1 v 60.8; P = .020). Live birth after ARTs were more common for HL survivors than for comparators (males 21.6% v 6.3%; P < .001; females 13.6% v 5.5%; P = .001). There were no differences in gestational age, Apgar score, or newborn measurements between HL survivors and matched comparators. CONCLUSION The parenthood rates for HL survivors who have not experienced relapse were generally similar to the general population. However, ARTs were used more often before the first live birth in HL survivors, which is relevant information when discussing possible long-term side effects and fertility-preserving treatment options.

Published
2021
Full Text
View/download PDF

30. Relapsed / Refractory International Prognostic Index (R/R-IPI):An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma

Author

Maurer, Matthew J., Jakobsen, Lasse H., Mwangi, Raphael, Schmitz, Norbert, Farooq, Umar, Flowers, Cristopher R., de Nully Brown, Peter, Thompson, Carrie A., Frederiksen, Henrik, Cunningham, David, Jørgensen, Judit, Poeschel, Viola, Nowakowski, Grzegorz, Seymour, John F., Merli, Francesco, Haioun, Corinne, Ghesquieres, Hervé, Ziepert, Marita, Tilly, Hervé, Salles, Gilles, Shi, Qian, El-Galaly, Tarec C., Habermann, Thomas M., Maurer, Matthew J., Jakobsen, Lasse H., Mwangi, Raphael, Schmitz, Norbert, Farooq, Umar, Flowers, Cristopher R., de Nully Brown, Peter, Thompson, Carrie A., Frederiksen, Henrik, Cunningham, David, Jørgensen, Judit, Poeschel, Viola, Nowakowski, Grzegorz, Seymour, John F., Merli, Francesco, Haioun, Corinne, Ghesquieres, Hervé, Ziepert, Marita, Tilly, Hervé, Salles, Gilles, Shi, Qian, El-Galaly, Tarec C., and Habermann, Thomas M.

Abstract

Disease progression after frontline therapy for Diffuse large B-cell lymphoma (DLBCL) is a clinically significant event. Patients who experience early progression or have refractory disease have especially poor outcomes. Simple, clinically applicable prognostic tools are needed for selecting patients for consideration for novel therapies and prognostication in the relapsed/refractory (R/R) setting. Model building was performed in patients from the Surrogate endpoints in aggressive lymphoma (SEAL) consortium with disease progression after frontline immunochemotherapy. The primary endpoint was overall survival (OS) measured from date of progression. Validation was performed in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (MER) and Danish National Lymphoma Register (LYFO) cohorts. Model performance was assessed using time-dependent concordance indices (c-statistic) and calibration with metrics evaluated at 2 years from progression. Note, 1234 of 5112 patients treated with frontline immunochemotherapy in the SEAL consortium developed progressive disease. Time to progression on immunochemotherapy and age at progression were strongly associated with post-progression OS (both p < 0.001). A prognostic model was developed incorporating spline fit for both variables. The model had good concordance in the discovery (0.67) and validation sets (LYFO c = 0.64, MER c = 0.68) with generally good calibration. Time to progression on frontline therapy is strongly associated with post-progression OS in DLBCL. We developed and validated a simple to apply clinical prognostic tool in the R/R setting. The useful prediction of expected outcomes in R/R DLBCL and can inform treatment decisions such as considerations for CAR-T therapy as well as trial designs. The model is available in smartphone-based point of care applications.

Published
2021

31. SARS‐CoV‐2 infection among patients with haematological disorders:Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study

Author

Glenthøj, Andreas, Jakobsen, Lasse H., Sengeløv, Henrik, Ahmad, Syed A., Qvist, Kristian, Rewes, Annika, Poulsen, Christian B., Overgaard, Ulrik M., Mølle, Ingolf, Severinsen, Marianne T., Strandholdt, Casper N., Maibom, Jack, Kodahl, Annette R., Ryg, Jesper, Ravn, Pernille, Johansen, Isik S., Helsø, Søren N., Jensen‐fangel, Søren, Kisielewicz, Jacek, Wiese, Lothar, Helleberg, Marie, Kirk, Ole, Clausen, Michael R., Frederiksen, Henrik, Glenthøj, Andreas, Jakobsen, Lasse H., Sengeløv, Henrik, Ahmad, Syed A., Qvist, Kristian, Rewes, Annika, Poulsen, Christian B., Overgaard, Ulrik M., Mølle, Ingolf, Severinsen, Marianne T., Strandholdt, Casper N., Maibom, Jack, Kodahl, Annette R., Ryg, Jesper, Ravn, Pernille, Johansen, Isik S., Helsø, Søren N., Jensen‐fangel, Søren, Kisielewicz, Jacek, Wiese, Lothar, Helleberg, Marie, Kirk, Ole, Clausen, Michael R., and Frederiksen, Henrik

Published
2021

32. Burkitt Lymphoma International Prognostic Index

Author

Olszewski, Adam J., primary, Jakobsen, Lasse H., additional, Collins, Graham P., additional, Cwynarski, Kate, additional, Bachanova, Veronika, additional, Blum, Kristie A., additional, Boughan, Kirsten M., additional, Bower, Mark, additional, Dalla Pria, Alessia, additional, Danilov, Alexey, additional, David, Kevin A., additional, Diefenbach, Catherine, additional, Ellin, Fredrik, additional, Epperla, Narendranath, additional, Farooq, Umar, additional, Feldman, Tatyana A., additional, Gerrie, Alina S., additional, Jagadeesh, Deepa, additional, Kamdar, Manali, additional, Karmali, Reem, additional, Kassam, Shireen, additional, Kenkre, Vaishalee P., additional, Khan, Nadia, additional, Kim, Seo-Hyun, additional, Klein, Andreas K., additional, Lossos, Izidore S., additional, Lunning, Matthew A., additional, Martin, Peter, additional, Martinez-Calle, Nicolas, additional, Montoto, Silvia, additional, Naik, Seema, additional, Palmisiano, Neil, additional, Peace, David, additional, Phillips, Elizabeth H., additional, Phillips, Tycel J., additional, Portell, Craig A., additional, Reddy, Nishitha, additional, Santarsieri, Anna, additional, Sarraf Yazdy, Maryam, additional, Smeland, Knut B., additional, Smith, Scott E., additional, Smith, Stephen D., additional, Sundaram, Suchitra, additional, Zayac, Adam S., additional, Zhang, Xiao-Yin, additional, Zhu, Catherine, additional, Cheah, Chan Y., additional, El-Galaly, Tarec C., additional, and Evens, Andrew M., additional

Published
2021
Full Text
View/download PDF

33. Relapsed/Refractory International Prognostic Index (R/ R‐IPI ): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma

Author

Maurer, Matthew J., primary, Jakobsen, Lasse H., additional, Mwangi, Raphael, additional, Schmitz, Norbert, additional, Farooq, Umar, additional, Flowers, Cristopher R., additional, Nully Brown, Peter, additional, Thompson, Carrie A., additional, Frederiksen, Henrik, additional, Cunningham, David, additional, Jørgensen, Judit, additional, Poeschel, Viola, additional, Nowakowski, Grzegorz, additional, Seymour, John F., additional, Merli, Francesco, additional, Haioun, Corinne, additional, Ghesquieres, Hervé, additional, Ziepert, Marita, additional, Tilly, Hervé, additional, Salles, Gilles, additional, Shi, Qian, additional, El‐Galaly, Tarec C., additional, and Habermann, Thomas M., additional

Published
2021
Full Text
View/download PDF

34. SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study

Author

Glenthøj, Andreas, primary, Jakobsen, Lasse H., additional, Sengeløv, Henrik, additional, Ahmad, Syed A., additional, Qvist, Kristian, additional, Rewes, Annika, additional, Poulsen, Christian B., additional, Overgaard, Ulrik M., additional, Mølle, Ingolf, additional, Severinsen, Marianne T., additional, Strandholdt, Casper N., additional, Maibom, Jack, additional, Kodahl, Annette R., additional, Ryg, Jesper, additional, Ravn, Pernille, additional, Johansen, Isik S., additional, Helsø, Søren N., additional, Jensen‐Fangel, Søren, additional, Kisielewicz, Jacek, additional, Wiese, Lothar, additional, Helleberg, Marie, additional, Kirk, Ole, additional, Clausen, Michael R., additional, and Frederiksen, Henrik, additional

Published
2020
Full Text
View/download PDF

36. Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients

Author

Øvlisen, Andreas K., primary, Jakobsen, Lasse H., additional, Kragholm, Kristian H., additional, Nielsen, René E., additional, Hutchings, Martin, additional, Dahl‐Sørensen, Rasmus B., additional, Frederiksen, Henrik, additional, Stoltenberg, Danny, additional, Bøgsted, Martin, additional, Østgård, Lene S. G., additional, Severinsen, Marianne T., additional, and El‐Galaly, Tarec C., additional

Published
2020
Full Text
View/download PDF

37. On estimating the time to statistical cure

Author

Jakobsen, Lasse H., primary, Andersson, Therese M.-L., additional, Biccler, Jorne L., additional, Poulsen, Laurids Ø., additional, Severinsen, Marianne T., additional, El-Galaly, Tarec C., additional, and Bøgsted, Martin, additional

Published
2020
Full Text
View/download PDF

38. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients

Author

Jakobsen, Lasse H., primary, Ellin, Fredrik, additional, Smeland, Knut B., additional, Wästerlid, Tove, additional, Christensen, Jacob H., additional, Jørgensen, Judit M., additional, Josefsson, Pär L., additional, Øvlisen, Andreas K., additional, Holte, Harald, additional, Blaker, Yngvild N., additional, Grauslund, Jacob H., additional, Bjørn, Jon, additional, Molin, Daniel, additional, Lagerlöf, Ingemar, additional, Smedby, Karin E., additional, Colvin, Katherine, additional, Thanarajasingam, Gita, additional, Maurer, Matthew J., additional, Habermann, Thomas M., additional, Song, Kevin W., additional, Zhu, Katie Y., additional, Gerrie, Alina S., additional, Cheah, Chan Y., additional, and El‐Galaly, Tarec C., additional

Published
2020
Full Text
View/download PDF

40. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients

Author

Jakobsen, Lasse H., Ellin, Fredrik, Smeland, Knut B., Wästerlid, Tove, Christensen, Jacob H., Jorgensen, Judit M., Josefsson, Pär L., Ovlisen, Andreas K., Holte, Harald, Blaker, Yngvild N., Grauslund, Jacob H., Bjorn, Jon, Molin, Daniel, Lagerlöf, Ingemar, Smedby, Karin E., Colvin, Katherine, Thanarajasingam, Gita, Maurer, Matthew J., Habermann, Thomas M., Song, Kevin W., Zhu, Katie Y., Gerrie, Alina S., Cheah, Chan Y., El-Galaly, Tarec C., Jakobsen, Lasse H., Ellin, Fredrik, Smeland, Knut B., Wästerlid, Tove, Christensen, Jacob H., Jorgensen, Judit M., Josefsson, Pär L., Ovlisen, Andreas K., Holte, Harald, Blaker, Yngvild N., Grauslund, Jacob H., Bjorn, Jon, Molin, Daniel, Lagerlöf, Ingemar, Smedby, Karin E., Colvin, Katherine, Thanarajasingam, Gita, Maurer, Matthew J., Habermann, Thomas M., Song, Kevin W., Zhu, Katie Y., Gerrie, Alina S., Cheah, Chan Y., and El-Galaly, Tarec C.

Abstract

Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0 center dot 6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0 center dot 4 (95% CI: -0 center dot 7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.

Published
2020
Full Text
View/download PDF

41. Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients

Author

Øvlisen, Andreas Kiesbye, primary, Jakobsen, Lasse H., additional, Kragholm, Kristian Hay, additional, Hutchings, Martin, additional, Frederiksen, Henrik, additional, Kamper, Peter, additional, Eloranta, Sandra, additional, Weibull, Caroline, additional, Glimelius, Ingrid, additional, Ekstroem Smedby, Karin Ekstrom, additional, Severinsen, Marianne Tang, additional, and El-Galaly, Tarec Christoffer C., additional

Published
2019
Full Text
View/download PDF

42. Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients

Author

Ellin, Fredrik, primary, Smeland, Knut B., additional, Wästerlid, Tove, additional, Christensen, Jacob H., additional, Jørgensen, Judit, additional, Josefsson, Pär L., additional, Holte, Harald, additional, Blaker, Yngvild Nuvin, additional, Grauslund, Jacob H., additional, Bjoern, Jon, additional, Molin, Daniel, additional, Lagerlöf, Ingemar, additional, Ekstroem Smedby, Karin Ekstrom, additional, Colvin, Katherine, additional, Thanarajasingam, Gita, additional, Maurer, Matthew J, additional, Habermann, Thomas M., additional, Song, Kevin, additional, Zhu, Katie Yuan, additional, Gerrie, Alina S, additional, Cheah, Chan Y., additional, El-Galaly, Tarec Christoffer C., additional, and Jakobsen, Lasse H., additional

Published
2019
Full Text
View/download PDF

43. Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Author

Maurer, Matthew J., primary, Jakobsen, Lasse H., primary, Schmitz, Norbert, primary, Farooq, Umar, primary, Flowers, Christopher R., primary, Brown, Peter de Nully, primary, Thompson, Carrie A., primary, Frederiksen, Henrik, primary, Cunningham, David, primary, Jørgensen, Judit, primary, Poeschel, Viola, primary, Nowakowski, Grzegorz, primary, Seymour, John F., primary, Merli, Francesco, primary, Haioun, Corinne, primary, Ghesquieres, Herve, primary, Ziepert, Marita, primary, Tilly, Herve, primary, Salles, Gilles, primary, Shi, Qian, primary, El-Galaly, Tarec Christoffer C., primary, and Habermann, Thomas M., primary

Published
2019
Full Text
View/download PDF

44. Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma

Author

Biccler, Jorne L., primary, Savage, Kerry J., additional, Brown, Peter D.N., additional, Jørgensen, Judit, additional, Larsen, Thomas S., additional, Poulsen, Christian B., additional, Stoltenberg, Danny, additional, Sehn, Laurie H., additional, Scott, David W., additional, Gerrie, Alina S., additional, Jakobsen, Lasse H., additional, Bøgsted, Martin, additional, El-Galaly, Tarec C., additional, and Villa, Diego, additional

Published
2019
Full Text
View/download PDF

45. Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma.

Author

Maurer, Matthew J., Jakobsen, Lasse H., Mwangi, Raphael, Schmitz, Norbert, Farooq, Umar, Flowers, Cristopher R., Nully Brown, Peter, Thompson, Carrie A., Frederiksen, Henrik, Cunningham, David, Jørgensen, Judit, Poeschel, Viola, Nowakowski, Grzegorz, Seymour, John F., Merli, Francesco, Haioun, Corinne, Ghesquieres, Hervé, Ziepert, Marita, Tilly, Hervé, and Salles, Gilles

Published
2021
Full Text
View/download PDF

46. Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma

Author

Biccler, Jorne L., Savage, Kerry J., Brown, Peter D.N., Jørgensen, Judit, Larsen, Thomas S., Poulsen, Christian B., Stoltenberg, Danny, Sehn, Laurie H., Scott, David W., Gerrie, Alina S., Jakobsen, Lasse H., Bøgsted, Martin, El-galaly, Tarec C., Villa, Diego, Biccler, Jorne L., Savage, Kerry J., Brown, Peter D.N., Jørgensen, Judit, Larsen, Thomas S., Poulsen, Christian B., Stoltenberg, Danny, Sehn, Laurie H., Scott, David W., Gerrie, Alina S., Jakobsen, Lasse H., Bøgsted, Martin, El-galaly, Tarec C., and Villa, Diego

Published
2019

47. SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study.

Author

Glenthøj, Andreas, Jakobsen, Lasse H., Sengeløv, Henrik, Ahmad, Syed A., Qvist, Kristian, Rewes, Annika, Poulsen, Christian B., Overgaard, Ulrik M., Mølle, Ingolf, Severinsen, Marianne T., Strandholdt, Casper N., Maibom, Jack, Kodahl, Annette R., Ryg, Jesper, Ravn, Pernille, Johansen, Isik S., Helsø, Søren N., Jensen‐Fangel, Søren, Kisielewicz, Jacek, and Wiese, Lothar

Subjects
*SARS-CoV-2, *ACUTE leukemia, *LYMPHOCYTIC leukemia, *CHRONIC leukemia, *OLDER patients, *LYMPHOPENIA
Abstract

Objectives: Patients with haematological disorders may be particularly vulnerable to respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection; however, this is unknown. Methods: We conducted a prospective, nationwide study including 66 patients in follow‐up at Danish haematology departments with a malignant or non‐malignant haematological disorder and with verified SARS‐CoV‐2 infection. Outcomes were intensive care unit (ICU) admission and one‐month survival rate. Results: Mean age was 66.7 years, 60.6% were males, 90.9% had comorbidity, and 13.6% had a BMI ≥ 30. The most frequent diagnoses were chronic lymphocytic leukaemia/lymphoma (47.0%), multiple myeloma (16.7%) and acute leukaemia/myelodysplastic syndrome (AL/MDS) (12.1%). Treatment for the haematological disease was ongoing in 59.1% of cases. Neutropenia was present in 6.5%, lymphopenia in 46.6% and hypogammaglobulinaemia in 26.3%. The SARS‐CoV‐2 infection was mild in 50.0%, severe in 36.4% and critical in 13.6%. After one month, 21.2% had been admitted to ICU, and 24.2% died. Mortality was highest in older patients, patients with severe/critical SARS‐CoV‐2 infection, high comorbidity score or high performance status score, purine analogue treatment and with AL/MDS. Although older patients and patients with comorbidities had the highest mortality rates, mortality was considerable among all haematological patients. Conclusion: Haematological patients with SARS‐CoV‐2 infection has a severe clinical course. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma

Author

Biccler, Jorne Lionel, primary, Savage, Kerry J, additional, Brown, Peter de Nully, additional, Jørgensen, Judit, additional, Larsen, Thomas Stauffer, additional, Poulsen, Christian Bjørn, additional, Stoltenberg, Danny, additional, Jakobsen, Lasse H., additional, Bøgsted, Martin, additional, Villa, Diego, additional, and El-Galaly, Tarec C., additional

Published
2018
Full Text
View/download PDF

49. Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients

Author

Jakobsen, Lasse H., primary, Ellin, Fredrik, additional, Smeland, Knut B., additional, Wästerlid, Tove, additional, Christensen, Jacob H., additional, Jørgensen, Judit, additional, Josefsson, Pär L., additional, Holte, Harald, additional, Blaker, Yngvild N., additional, Grauslund, Jacob H., additional, Bjørn, Jon, additional, Molin, Daniel, additional, Lagerlöf, Ingemar, additional, Ekstroem Smedby, Karin, additional, Colvin, Katherine, additional, Thanarajasingam, Gita, additional, Gerrie, Alina S., additional, Cheah, Chan Y., additional, and El-Galaly, Tarec C., additional

Published
2018
Full Text
View/download PDF

50. Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients

Author

Biccler, Jorne Lionel, primary, Glimelius, Ingrid, additional, Eloranta, Sandra, additional, Smeland, Knut B., additional, Brown, Peter de Nully, additional, Jakobsen, Lasse H., additional, Frederiksen, Henrik, additional, Jerkeman, Mats, additional, Fosså, Alexander, additional, Andersson, Therese M.L., additional, Holte, Harald, additional, Bøgsted, Martin, additional, El-Galaly, Tarec C., additional, and Ekstroem Smedby, Karin, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results